Analyzing CareFusion (CFN) and C.R. Bard (BCR)
CareFusion (NYSE: CFN) and C.R. Bard (NYSE:BCR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.
Valuation and Earnings
This table compares CareFusion and C.R. Bard’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|C.R. Bard||$3.83 billion||6.11||$1.18 billion||$7.61||42.30|
C.R. Bard has higher revenue and earnings than CareFusion.
C.R. Bard pays an annual dividend of $1.04 per share and has a dividend yield of 0.3%. CareFusion does not pay a dividend. C.R. Bard pays out 13.7% of its earnings in the form of a dividend. CareFusion has increased its dividend for 45 consecutive years.
This table compares CareFusion and C.R. Bard’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
79.3% of C.R. Bard shares are owned by institutional investors. 0.8% of C.R. Bard shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for CareFusion and C.R. Bard, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
C.R. Bard has a consensus target price of $276.38, suggesting a potential downside of 14.14%. Given C.R. Bard’s higher probable upside, analysts clearly believe C.R. Bard is more favorable than CareFusion.
C.R. Bard beats CareFusion on 8 of the 11 factors compared between the two stocks.
CareFusion Company Profile
CareFusion Corporation is a global medical technology company. The Company operates in two business segments: Medical Systems and Procedural Solutions. The Company’s primary product brands include: Alaris intravenous (IV) infusion systems; Pyxis and Rowa automated medication dispensing and supply management systems; AVEA, Vela and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus, MaxZero, SmartSite and Texium needle-free IV infusion valves, administration sets and accessories; V. Mueller and Snowden-Pencer open surgical and laparoscopic instrumentation; PleurX, Achieve and Temno interventional specialty products; AirLife disposable ventilator circuits and oxygen masks used for providing respiratory therapy; Vital Signs single-use consumables for respiratory care and anesthesiology; Jaeger and SensorMedics cardiopulmonary diagnostic equipment, and MedMined data mining surveillance software and analytics.
C.R. Bard Company Profile
C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
Receive News & Ratings for CareFusion Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareFusion Co. and related companies with MarketBeat.com's FREE daily email newsletter.